Advent's $715M NZCR Buy Sets Up ANZ Healthcare Expansion

Advent International agreed to acquire New Zealand Clinical Research for about $715 million in a no-competition deal, the second healthcare transaction from its Sydney office since opening in 2024 and a marker of the Boston firm's expanding Asia-Pacific footprint.

"It remained proprietary, no process, confidential and very, very closely managed," Beau Dixon, managing director and head of Australia and New Zealand at Advent, said in an interview.

The transaction, expected to close in the December quarter, values NZCR at about $715 million. Advent sees potential to double NZCR's annual revenue within three to five years through organic growth, Dixon said. The firm manages $94 billion in assets globally and typically works on pipeline opportunities for up to 18 months before closing a transaction. Payment structure and regulatory approval requirements were not disclosed.

The NZCR deal follows Advent's January opening of a Tokyo office and its May acquisition of Japan Wellbeing, a provider of home care for the aged — the firm's first direct investment in Japan. Advent's Australia office opened in Sydney in 2024, and NZCR represents its second deal from that base.

Dixon said he approached NZCR's existing shareholders, including Auckland-based Waterman Capital, after identifying the clinical research network as a target. The proprietary nature of the deal — sealed without a competitive auction — reflects Advent's ability to source opportunities through direct relationships in a market where clinical research services remain relatively fragmented.

"We are looking at other areas in health where we feel that we have the requisite conviction based on prior experience," Dixon said, noting that Advent is not currently pursuing acquisitions directly adjacent to NZCR's clinical research value chain.

Advent's healthcare expertise draws on earlier investments including Syneos Health, a pharma research services provider, and Simtra, a biotechnology manufacturer. U.S.-based colleagues with deep healthcare sector knowledge assisted on the NZCR transaction, Dixon said.

The acquisition reflects growing private equity appetite for healthcare services assets across Asia-Pacific. Specialist healthcare funds such as Singapore-based CBC Group have been expanding their regional footprint, while generalist firms including Advent are increasingly targeting clinical research, home care and other health services businesses that benefit from aging populations and rising healthcare spending.

The broader APAC healthcare investment thesis has shifted in recent years. At the Asia Bio Partnering Forum in Singapore this month, industry participants noted that capital is increasingly interested in Asia because of the quality and volume of healthcare opportunities emerging from the region — but that being an "Asian biotech" is not by itself an investment thesis. Companies still need to demonstrate differentiation, defensible intellectual property and a credible path to value creation.

For Advent, the ANZ market offers sophisticated clinical trial infrastructure and a regulatory environment aligned with global standards. Australia's early-stage clinical research capabilities were highlighted at the same Singapore forum, where participants noted the country's complementary role in the regional healthcare value chain alongside innovation hubs in China, Singapore, Japan and Korea.

Dixon said there is no specific timeline pressure for the next deal. "There is no time limit on when we could sign the next deal and there's no specific pressure around that," he said. "The support is there for these high conviction opportunities."

The NZCR closing in the December quarter will mark a milestone in Advent's ANZ strategy. With $94 billion in assets under management and a growing regional presence across Sydney and Tokyo, the firm is positioned to pursue further healthcare acquisitions in Australia and New Zealand as it builds out its Asia-Pacific platform.

This article is for informational purposes only and does not constitute investment advice.